Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer - 18/08/11
Address for correspondence: Tomasz M. Beer, M.D., Department of Medicine, Oregon Health & Science University, Mail Code CR145, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239.Abstract |
A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported in part by PHS grants 5 M01 RR00334-33S2 and 20000775-001 from Praecis Pharmaceuticals. |
Vol 65 - N° 4
P. 799 - avril 2005 Retour au numéro
Article précédent
- Medial thigh pain: Neurology or urology?
- Chris Antolak, Benjamin Canales, Manoj Monga
- Pitfall in renal cyst surgery: Serous cystadenoma of pancreas mimicking renal cyst
- Alexander Bachmann, Robin Ruszat, Stephen Wyler, Roberto Casella, Igor Langer, Thomas C. Gasser, Tullio Sulser
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?